[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2019142053A3 - Therapeutic inhibitory compounds - Google Patents

Therapeutic inhibitory compounds Download PDF

Info

Publication number
WO2019142053A3
WO2019142053A3 PCT/IB2019/000079 IB2019000079W WO2019142053A3 WO 2019142053 A3 WO2019142053 A3 WO 2019142053A3 IB 2019000079 W IB2019000079 W IB 2019000079W WO 2019142053 A3 WO2019142053 A3 WO 2019142053A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitory compounds
compounds
therapeutic inhibitory
useful
inhibition
Prior art date
Application number
PCT/IB2019/000079
Other languages
French (fr)
Other versions
WO2019142053A2 (en
Inventor
Andrew Mcdonald
Shawn QIAN
Original Assignee
Lifesci Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lifesci Pharmaceuticals, Inc. filed Critical Lifesci Pharmaceuticals, Inc.
Publication of WO2019142053A2 publication Critical patent/WO2019142053A2/en
Publication of WO2019142053A3 publication Critical patent/WO2019142053A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like.
PCT/IB2019/000079 2018-01-17 2019-01-17 Therapeutic inhibitory compounds WO2019142053A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862618578P 2018-01-17 2018-01-17
US62/618,578 2018-01-17

Publications (2)

Publication Number Publication Date
WO2019142053A2 WO2019142053A2 (en) 2019-07-25
WO2019142053A3 true WO2019142053A3 (en) 2019-11-14

Family

ID=67302024

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2019/000079 WO2019142053A2 (en) 2018-01-17 2019-01-17 Therapeutic inhibitory compounds

Country Status (1)

Country Link
WO (1) WO2019142053A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111303035A (en) * 2020-03-18 2020-06-19 徐州圣元化工有限公司 Preparation method of 3- (difluoromethyl) -1-methyl-1H-pyrazole-4-carboxylic acid
WO2024059186A1 (en) * 2022-09-15 2024-03-21 Takeda Pharmaceutical Company Limited N-((isoquinolin-6-yl)methyl)-1h-pyrazole-4-carboxamid derivatives as plasma kallikrein inhibitors for the treatment of hereditary angioedema

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170029406A1 (en) * 2015-07-01 2017-02-02 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
WO2018011628A1 (en) * 2016-07-11 2018-01-18 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9611252B2 (en) * 2013-12-30 2017-04-04 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
US20170260163A1 (en) * 2013-12-30 2017-09-14 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
US20170029406A1 (en) * 2015-07-01 2017-02-02 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
WO2018011628A1 (en) * 2016-07-11 2018-01-18 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds

Also Published As

Publication number Publication date
WO2019142053A2 (en) 2019-07-25

Similar Documents

Publication Publication Date Title
WO2017001926A3 (en) Therapeutic inhibitory compounds
WO2017001936A3 (en) Therapeutic inhibitory compounds
MX2017000450A (en) Therapeutic inhibitory compounds.
SA518400547B1 (en) Pyrazolopyrimidine Derivatives as Kinase Inhibitor
WO2017098328A8 (en) Therapeutic inhibitory compounds
WO2016118951A3 (en) Heterocyclic itk inhibitors for treating inflammation and cancer
WO2015168466A8 (en) Inhibitors of lysine specific demethylase-1
WO2017035353A8 (en) Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders
CA2983481A1 (en) Janus kinase inhibitor
TN2020000125A1 (en) Amino-fluoropiperidine derivative as kinase inhibitor
MY197116A (en) Bicyclic heterocyclyl derivatives as irak4 inhibitors
NZ724250A (en) Human plasma kallikrein inhibitors
SA520412335B1 (en) Oxy-fluoropiperidine derivatives as kinase inhibitor
MX2017011000A (en) Substituted pyrazole compounds as serine protease inhibitors.
WO2018015818A3 (en) Therapeutic inhibitory compounds
MX2022005256A (en) Cd73 inhibitors.
MX2021010297A (en) Human plasma kallikrein inhibitors.
EP3999121A4 (en) Treatment/prevention of disease by linc complex inhibition
WO2016004413A3 (en) Gls1 inhibitors for treating disease
WO2018229543A3 (en) Therapeutic inhibitory compounds
WO2019142053A3 (en) Therapeutic inhibitory compounds
PH12017501668A1 (en) Bace1 inhibitors
PH12019502046A1 (en) Pyrrolotriazine derivatives as kinase inhibitor
WO2020106751A8 (en) Inhibitors of gli1 as therapeutic agents
WO2016144704A3 (en) Heterocyclic autotaxin inhibitor compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19740945

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19740945

Country of ref document: EP

Kind code of ref document: A2